DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Hochhaus A, Saglio G, Hughes TP. et al.
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.
Leukemia 2016;
30: 1044-1054
We do not assume any responsibility for the contents of the web pages of other providers.